Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer ’s disease

ConclusionsOur results show an ultra-deep serum discovery study by TMT –LC/LC–MS/MS, and a validation experiment by TOMAHAQ targeted LC–MS3. The MS-based discovery and validation methods are of general use for biomarker discovery from complex biofluids (e.g. serum proteome). This pilot study also identified deregulated proteins, in particular proteins associated with mitochondrial function in the AD serum samples. These proteins may serve as novel AD candidate biomarkers.
Source: Clinical Proteomics - Category: Biochemistry Source Type: research